• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » More evidence that antipsychotics are dangerous in dementia

More evidence that antipsychotics are dangerous in dementia

July 1, 2007
Jesse H. Wright, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Jesse H. Wright, MD. Professor and Chief of Adult Psychiatry, University of Louisville School of Medicine, Co-author, Learning Cognitive Behavior Therapy: An Illustrated Guide.

Dr. Wright has disclosed that he receives royalities from books he has written about cognitive behavioral therapy.

Subject:
Antipsychotics

Short Description:
More evidence that antipsychotics are dangerous in dementia

Background:
In 2005, the FDA issued a health advisory saying that antipsychotics appear to increase the risk of death in elderly patients with dementia. That advisory was based on data from placebo-controlled trials of antipsychotics conducted by industry. Now, a new study based on a completely different, and much larger, dataset, appears to confirm these dangers. Researchers used comprehensive medical records available through Canada’s health system to identify all elderly patients treated for dementia from 1997 to 2002 in the province of Ontario. A total of 27,259 patient records were examined. The researchers found that after 30 days of taking atypical antipsychotics, patients had a mortality rate of 3.9%, while matched patients on no antipsychotics had a mortality rate of 2.7%, meaning that atypicals increased the risk of early death by a factor of 1.55. Researchers had enough data to compare conventional agents vs. atypicals, and found that conventionals were riskier than atypicals by a factor of about 1.25 (Gill SS et al., Ann Intern Med 2007;146:775-786).

TCPR's Take:
The relative risk looks large, but the absolute risk is only 1.2%, meaning that atypicals would cause roughly one excess death out of each 100 patients treated with atypicals. The question is whether this small risk is overshadowed by the quality-of-life benefit agitated patients derive from being on antipsychotics. Many would argue that antipsychotics are worth this risk.

For more on this topic, see The Carlat Geriatric Psychiatry Report.

General Psychiatry
KEYWORDS antipsychotics dementia geriatric psychiatry
Jesse H. Wright, MD

Latest CATIE results: Atypicals no better than Trilafon for improving cognition

More from this author
www.thecarlatreport.com
Issue Date: July 1, 2007
SUBSCRIBE NOW
Table Of Contents
Does Psychotherapy Work?
Psychotherapy: A Practical and Integrative Approach
High Yield Cognitive-Behavior Therapy Techniques
Zoloft not helpful for subsyndromal symptoms in cancer patients
More evidence that antipsychotics are dangerous in dementia
Is divorce a risk factor for getting a stimulant prescription?
Latest CATIE results: Atypicals no better than Trilafon for improving cognition
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.